← All trials
NCT06994676
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2025
- Primary completion
- Jan 31, 2027
- Completion date
- Jun 30, 2027
- First posted
- May 29, 2025
- Last posted
- Sep 22, 2025
- Enrollment
- 72
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Crossbow Therapeutics, Inc.Lead sponsor
- Crossbow Therapeutics, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.